Health Affairs Lists Pros And Cons Of Int’l Reference Drug Pricing

By John Wilkerson / September 10, 2019 at 12:47 PM
Instead of tying Medicare Part B drug prices to prices paid abroad, it might make more sense for U.S. government officials to negotiate prices on their own, according to a Health Affairs article written by USC-Brookings Schaeffer Initiative for Health Policy staff. However, were Congress to run with the administration’s informally proposed International Pricing Index, the authors suggest Congress could expand the program to Medicare Part D, Medicaid and the commercial market. It would likely be difficult to determine...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.